Intrapulmonary Percussive Ventilation (IPV) Versus Nasal Continuous Positive Airway Pressure Ventilation (nCPAP) in Transient Respiratory Distress of the Newborn (HFPV)
This study has been completed.
Sponsor:
University Hospital, Bordeaux
Information provided by:
University Hospital, Bordeaux
ClinicalTrials.gov Identifier:
NCT00556738
First received: November 9, 2007
Last updated: May 12, 2010
Last verified: May 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
During caesarean section, transient respiratory distress which occurs frequently (3%) with possible complications are at present managed by non invasive nasal continuous positive airway pressure ventilation (nCPAP) associated with oxygen therapy. Intrapulmonary Percussive Ventilation (IPV) is a non-invasive ventilatory mode used in some intensive care units to treat some respiratory distress syndrome of the newborn with a good tolerance, but without evaluation in prospective studies
| Condition | Intervention |
|---|---|
|
Respiratory Distress Syndrome, Newborn |
Procedure: Nasal Continuous Positive Airway Pressure ventilation Procedure: Intrapulmonary Percussive Ventilation |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Intrapulmonary Percussive Ventilation and Nasal Continuous Positive Airway Pressure Ventilation in Transient Respiratory Distress of the Newborn: A Randomized Controlled Trial |
Further study details as provided by University Hospital, Bordeaux:
Primary Outcome Measures:
- Difference in time (min) required to normalize the respiratory distress (modified Silverman score = 0, no need for oxygen, RF < 50 bpm and SaO2 > 92%) between the two ventilatory modes [ Time Frame: Within the first 6 hours after birth ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Number of pneumothorax, lung infections, transfer to intensive care service, time of oxygenotherapy [ Time Frame: Within the first 72 hours after birth ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 100 |
| Study Start Date: | November 2007 |
| Study Completion Date: | December 2009 |
| Primary Completion Date: | December 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: nHFPV
Intrapulmonary Percussive Ventilation
|
Procedure: Intrapulmonary Percussive Ventilation
Intrapulmonary Percussive Ventilation
|
|
Active Comparator: nCPAP
Nasal Continuous Positive Airway Pressure ventilation
|
Procedure: Nasal Continuous Positive Airway Pressure ventilation
Nasal Continuous Positive Airway Pressure ventilation
|
Detailed Description:
- Principal Objective: To show that IPV ventilation can decrease the duration of transient respiratory distress as well as the risk of complications.
- Secondary Objective: Comparison between the two groups regarding: Length of oxygen therapy, complications (pneumothorax, pulmonary infections), need for intensive care hospitalization
- Study design: Open, prospective randomized trial.
- Inclusion criteria: Neonates with gestational age ≥ 35 weeks and weight ≥ 2000g, caesarean section, respiratory distress syndrome (modified Silverman score > 5, SpO2 < 90%), management within 20 minutes after birth.
- Exclusion criteria: clinical thoracic retraction, congenital lung malformation, meconium aspiration, neonatal infection, other congenital malformations.
- Study plan: After the screening evaluation and written consent document, neonates will be randomized into two groups: nCPAP ventilation or IPV. During the 6 hours after randomization, clinical data will be monitored: cardiac and respiratory frequency (CF -RF), saturation (SaO2), oxygenotherapy, Silverman Score. Then, neonates will be supervised 3 days after normalization of the respiratory distress.
- Number of subjects: 100 (50 in each group)
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Caesarean newborn
- Gestational age ≥ 35 weeks
- Weight ≥ 2 kg
- SaO2 < 90% after 10 min of life
- Silverman score ≥ 5
- Treated less than 20 min after birth
- Social security affiliation (parents)
- Informed consent signed (parents)
Exclusion Criteria:
- Thoracic retraction
- Congenital intrathoracic malformations
- Meconium aspiration
- Early neonatal infections with hemodynamic troubles
- Severe neonatal asphyxia
- Polymalformative syndrome
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00556738
Locations
| France | |
| Néonatalogie - Maternité - Hôpital Pellegrin | |
| Bordeaux, France, 33076 | |
Sponsors and Collaborators
University Hospital, Bordeaux
Investigators
| Principal Investigator: | Clothilde Bertrand, Dr | University Hospital, Bordeaux |
More Information
No publications provided
| Responsible Party: | Jean-Pierre LEROY / Clinical research and Innovation director, University hospital, Bordeaux |
| ClinicalTrials.gov Identifier: | NCT00556738 History of Changes |
| Other Study ID Numbers: | CHUBX 2007/09, 2007-A00666-47 |
| Study First Received: | November 9, 2007 |
| Last Updated: | May 12, 2010 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by University Hospital, Bordeaux:
|
HFPV neonatal respiratory distress |
Additional relevant MeSH terms:
|
Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Lung Diseases Respiratory Tract Diseases |
Respiration Disorders Infant, Premature, Diseases Infant, Newborn, Diseases |
ClinicalTrials.gov processed this record on May 23, 2013